Molecular structure of SGX-523, CAS Number: 1022150-57-7
SGX-523 (CAS 1022150-57-7)
Application:
SGX-523 is a Met inhibitor
CAS Number:
1022150-57-7
Molecular Weight:
359.41
Molecular Formula:
C18H13N7S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SGX-523 is an exquisitely selective Met (receptor tyrosine kinase) inhibitor with an IC50 of 4 nM.
SGX-523 (CAS 1022150-57-7) References
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. | Buchanan, SG., et al. 2009. Mol Cancer Ther. 8: 3181-90. PMID: 19934279
- Small molecule c-Met kinase inhibitors: a review of recent patents. | Porter, J. 2010. Expert Opin Ther Pat. 20: 159-77. PMID: 20100000
- FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. | Zhang, L., et al. 2015. Oncoscience. 2: 419-427. PMID: 26097875
- c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. | Shen, A., et al. 2015. Cancer Res. 75: 4548-59. PMID: 26483207
- Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors. | Zhao, J., et al. 2016. Bioorg Med Chem. 24: 3483-93. PMID: 27288183
- Novel [1,2,4] Triazol [4,3-a] Pyridine Derivatives as Potential Selective c-Met Inhibitors with Improved Pharmacokinetic Properties. | Zhao, J., et al. 2017. Anticancer Agents Med Chem. 17: 1102-1112. PMID: 27804848
- MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. | Ninomiya, K., et al. 2018. Sci Rep. 8: 1955. PMID: 29386539
- Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype. | Chen, X., et al. 2021. Mol Cancer Res. 19: 2026-2035. PMID: 34593609
- Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. | Vigoda, M., et al. 2022. Cancer Biol Ther. 23: 310-318. PMID: 35343367
- Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer. | Wang, Y., et al. 2023. Pharmacol Res Perspect. 11: e01047. PMID: 36583451
Inhibitor of:
Met.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SGX-523, 5 mg | sc-364616 | 5 mg | $255.00 | |||
SGX-523, 25 mg | sc-364616A | 25 mg | $681.00 |